Characteristics | N = 91 |
---|---|
Current follow-up | 75 (83.3) |
Duration of follow-up (months) | 44 (17–67) |
Disease status at the last medical evaluation | |
Active disease (clinical relapse) | 30 (33.0) |
Complete clinical response | 44 (48.4) |
Disease remission | 17 (18.7) |
Treatment | |
Previous IVMP pulse therapy | 70 (76.9) |
Previous IVIg | 54 (59.3) |
Previous IVIg + IVMP pulse therapy | 50 (54.9) |
No IVMP or IVIg | 14 (15.4) |
Current treatment | |
Glucocorticoid | |
Current use | 30 (33.0) |
Current dose (prednisone equivalent), mg/day | 0.0 (0.0–7.5) |
Immunosuppressive/immunomodulatory/immunobiological | |
Methotrexate | 21 (23.1) |
Azathioprine | 12 (13.2) |
Mycophenolate mofetil | 12 (13.2) |
Leflunomide | 8 (8.8) |
Cyclosporine | 3 (3.3) |
Cyclophosphamide | 1 (1.1) |
Rituximab | 30 (33.0) |